LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
The deal marks the latest in a string of agreements Transgenomic has signed for its non-core assets as it focuses on ICE-COLD PCR molecular diagnostics.
During a case management conference last week, Premaitha said the EC's competition department contacted it regarding an investigation into Illumina and Sequenom.
Although Sequenom had garnered support from a diverse range of groups who wanted clarity on patent eligibility, the Supreme Court denied the petition.
The lawsuit is one of several international patent infringement suits the firm is pursuing after its US NIPT patent was ruled ineligible.
The GenomeWeb Index rose 4 percent in May, in line with the Nasdaq and the Nasdaq Biotech Index, and outperforming the Dow Jones Industrial Average.
The initiative, launched last year by Quest and the French National Institute of Health and Medical Research, has reclassified 375 variants of unknown significance so far.
Sequenom's first quarter revenues dropped and the company ran fewer tests as more laboratories licensed the rights to develop their own NIPTs.
Sequenom has secured in-network status with seven state Anthem BCBS plans to provide NIPT to both high- and average-risk pregnancies.
Petitioners want the Supreme Court to clarify prior court cases for determining the patent eligibility of subject matter in order to prevent overinterpretation.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.